FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802207132> ?p ?o ?g. }

• W2802207132 endingPage "e301" @default.
• W2802207132 startingPage "e295" @default.
• W2802207132 abstract "Background The strict recruitment criteria of patients for clinical trials often lead to reduced generalizability of the findings. We studied how ponatinib is used outside clinical trials in patients with chronic myeloid leukemia (CML). Patients and Methods The present retrospective study included all patients with a diagnosis of CML who had received ponatinib in 7 medical centers in Israel. Results From 2011 to 2016, we identified 37 patients with CML who had received ponatinib, 21 in the chronic phase and 16 in the advanced phase. Only 9 patients (26%) harbored the T315I (threonine to isoleucine mutation at position 315) mutation. All patients had received ≥ 1 previous tyrosine kinase inhibitor. The median age in our cohort was 43 years (range, 9-82 years), significantly younger than expected for patients with relapsed or refractory CML and 20 years younger than the median age of patients who participated in the PACE (ponatinib Philadelphia-positive acute lymphoblastic leukemia and CML evaluation) trial. During a median follow-up of 14 months (range, 1-51 months), the overall response rate was 85%. Of 34 patients, 16 (47%) experienced at least a major molecular response. Of the 37 total patients, another 16 patients (43%) discontinued treatment because of disease progression (n = 6), vascular complications (n = 1), severe cytopenia (n = 2), or for other reasons (n = 7). Conclusion In real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates." @default.
• W2802207132 created "2018-05-17" @default.
• W2802207132 creator A5009040323 @default.
• W2802207132 creator A5019626882 @default.
• W2802207132 creator A5020614652 @default.
• W2802207132 creator A5032244232 @default.
• W2802207132 creator A5034356995 @default.
• W2802207132 creator A5040530806 @default.
• W2802207132 creator A5050422684 @default.
• W2802207132 creator A5053411706 @default.
• W2802207132 creator A5067332322 @default.
• W2802207132 creator A5083122598 @default.
• W2802207132 creator A5086557065 @default.
• W2802207132 date "2018-07-01" @default.
• W2802207132 modified "2023-10-11" @default.
• W2802207132 title "Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study" @default.
• W2802207132 cites W1418483084 @default.
• W2802207132 cites W1814874339 @default.
• W2802207132 cites W1907713465 @default.
• W2802207132 cites W1968747503 @default.
• W2802207132 cites W2009491041 @default.
• W2802207132 cites W2104694028 @default.
• W2802207132 cites W2110648386 @default.
• W2802207132 cites W2147109509 @default.
• W2802207132 cites W2171483455 @default.
• W2802207132 cites W2206259485 @default.
• W2802207132 cites W2331849216 @default.
• W2802207132 cites W2339943063 @default.
• W2802207132 cites W2608124271 @default.
• W2802207132 cites W2979708042 @default.
• W2802207132 doi "https://doi.org/10.1016/j.clml.2018.05.002" @default.
• W2802207132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29773429" @default.
• W2802207132 hasPublicationYear "2018" @default.
• W2802207132 type Work @default.
• W2802207132 sameAs 2802207132 @default.
• W2802207132 citedByCount "19" @default.
• W2802207132 countsByYear W28022071322019 @default.
• W2802207132 countsByYear W28022071322020 @default.
• W2802207132 countsByYear W28022071322021 @default.
• W2802207132 countsByYear W28022071322022 @default.
• W2802207132 countsByYear W28022071322023 @default.
• W2802207132 crossrefType "journal-article" @default.
• W2802207132 hasAuthorship W2802207132A5009040323 @default.
• W2802207132 hasAuthorship W2802207132A5019626882 @default.
• W2802207132 hasAuthorship W2802207132A5020614652 @default.
• W2802207132 hasAuthorship W2802207132A5032244232 @default.
• W2802207132 hasAuthorship W2802207132A5034356995 @default.
• W2802207132 hasAuthorship W2802207132A5040530806 @default.
• W2802207132 hasAuthorship W2802207132A5050422684 @default.
• W2802207132 hasAuthorship W2802207132A5053411706 @default.
• W2802207132 hasAuthorship W2802207132A5067332322 @default.
• W2802207132 hasAuthorship W2802207132A5083122598 @default.
• W2802207132 hasAuthorship W2802207132A5086557065 @default.
• W2802207132 hasConcept C126322002 @default.
• W2802207132 hasConcept C167135981 @default.
• W2802207132 hasConcept C187212893 @default.
• W2802207132 hasConcept C2777413986 @default.
• W2802207132 hasConcept C2777583451 @default.
• W2802207132 hasConcept C2778715236 @default.
• W2802207132 hasConcept C2778729363 @default.
• W2802207132 hasConcept C2780007613 @default.
• W2802207132 hasConcept C2780366003 @default.
• W2802207132 hasConcept C2780381907 @default.
• W2802207132 hasConcept C2908647359 @default.
• W2802207132 hasConcept C535046627 @default.
• W2802207132 hasConcept C71924100 @default.
• W2802207132 hasConcept C72563966 @default.
• W2802207132 hasConcept C99454951 @default.
• W2802207132 hasConceptScore W2802207132C126322002 @default.
• W2802207132 hasConceptScore W2802207132C167135981 @default.
• W2802207132 hasConceptScore W2802207132C187212893 @default.
• W2802207132 hasConceptScore W2802207132C2777413986 @default.
• W2802207132 hasConceptScore W2802207132C2777583451 @default.
• W2802207132 hasConceptScore W2802207132C2778715236 @default.
• W2802207132 hasConceptScore W2802207132C2778729363 @default.
• W2802207132 hasConceptScore W2802207132C2780007613 @default.
• W2802207132 hasConceptScore W2802207132C2780366003 @default.
• W2802207132 hasConceptScore W2802207132C2780381907 @default.
• W2802207132 hasConceptScore W2802207132C2908647359 @default.
• W2802207132 hasConceptScore W2802207132C535046627 @default.
• W2802207132 hasConceptScore W2802207132C71924100 @default.
• W2802207132 hasConceptScore W2802207132C72563966 @default.
• W2802207132 hasConceptScore W2802207132C99454951 @default.
• W2802207132 hasIssue "7" @default.
• W2802207132 hasLocation W28022071321 @default.
• W2802207132 hasLocation W28022071322 @default.
• W2802207132 hasOpenAccess W2802207132 @default.
• W2802207132 hasPrimaryLocation W28022071321 @default.
• W2802207132 hasRelatedWork W2011448032 @default.
• W2802207132 hasRelatedWork W2252716012 @default.
• W2802207132 hasRelatedWork W2314058894 @default.
• W2802207132 hasRelatedWork W2606453016 @default.
• W2802207132 hasRelatedWork W2802017747 @default.
• W2802207132 hasRelatedWork W3036978401 @default.
• W2802207132 hasRelatedWork W3176823109 @default.
• W2802207132 hasRelatedWork W4283524715 @default.
• W2802207132 hasRelatedWork W4362507290 @default.
• W2802207132 hasRelatedWork W4385064107 @default.

• next